Australia markets open in 2 hours 55 minutes
  • ALL ORDS

    6,811.30
    -0.90 (-0.01%)
     
  • AUD/USD

    0.7404
    +0.0026 (+0.35%)
     
  • ASX 200

    6,590.20
    +1.70 (+0.03%)
     
  • OIL

    45.25
    +0.70 (+1.57%)
     
  • GOLD

    1,833.10
    +14.20 (+0.78%)
     
  • BTC-AUD

    25,771.74
    +38.23 (+0.15%)
     
  • CMC Crypto 200

    374.19
    +9.27 (+2.54%)
     

Immutep Granted European Patent for IMP761

Immutep Limited
·2-min read

SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 3344654) entitled “Anti-LAG-3 Antibodies” by the European Patent Office.

The claims of the patent are directed to Immutep’s pre-clinical product candidate, IMP761, and also to the use of IMP761 in the treatment of T-cell mediated inflammatory and autoimmune diseases. The expiry date of the patent is 1 September 2036.

Immutep CEO, Marc Voigt stated: “IMP761 is the first agonist antibody that targets the immune checkpoint LAG-3 and aims to treat the root cause of autoimmune diseases such as, for example, inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis. It is very pleasing to see the grant of this patent in the important European market which will underpin ongoing investment in this promising product candidate.”

Immutep CSO and CMO, Dr. Frederic Triebel also stated: “There continues to be a significant unmet medical need for patients with various autoimmune diseases and so it is highly encouraging to see the recent progress being made with IMP761 towards clinical development, both in terms of cell line development announced in April 2020 and now with securing intellectual property protection.”

About IMP761
IMP761 is a first-in-class immunosuppressive agonist antibody to LAG-3. As a targeted immunosuppressive antibody, IMP761 has the potential to address the root cause of autoimmune diseases by specifically silencing the autoimmune memory T cells accumulating at the disease site which express LAG-3 as an exhaustion marker after being repeatedly stimulated with dominant self-peptides.

In April 2020, Immutep announced that its partner, Batavia Biosciences, had developed a pharmaceutical-grade, stable CHO cell line that produces significantly high product yields of IMP761. The Company will now complete the preparations for the Good Manufacturing Practice (GMP) process compliance development phase, ahead of commencement of clinical testing of the candidate in autoimmune disease.

In addition, in early 2019 Immutep reported encouraging preclinical results from its studies with IMP761. The in vivo studies showed that IMP761 decreases inflammatory T cell infiltration induced by intra-dermal injection of an antigen. These findings were published in the Journal of Immunology in January 2020.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com